3 results
Approved WMOCompleted
The BioNIR is non-inferior to the Resolute for the primary angiographic of in-stent late loss at 6 months
Approved WMOPending
Main objective: to assess the effects of PEG treatment on bile acid homeostasis in cystic fibrosis patients. Secondary objective: to assess the effects of PEG treatment on gastrointestinal symptoms and quality of life, and on gut health-related…
Approved WMOCompleted
1) The BioNIR is non-inferior to the Resolute for the primary clinical endpoint of target lesion failure (TLF) (defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR) at 12 months2/ The BioNIR is non-inferior to…